{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:15:39Z","timestamp":1791926139854,"version":"4.3.4"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-11847-2","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T08:27:57Z","timestamp":1778315277000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The JAK\/STAT pathway: key mechanism in gene activation, disease regulation, and emerging therapeutic targets"],"prefix":"10.1007","volume":"53","author":[{"given":"Jehan","family":"Mohamed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Habiba","family":"Ezat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana","family":"Abdelrahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rowana","family":"Abdelaziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem","family":"Ayman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"El-Khawaga","family":"OY","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghda W.","family":"Magar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,9]]},"reference":[{"issue":"1","key":"11847_CR1","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","volume":"66","author":"JJ O\u2019Shea","year":"2015","unstructured":"O\u2019Shea JJ, Schwartz DM, Villarino AV, Gadina M, McInnes IB, Laurence A (2015) The JAK-STAT pathway: Impact on human disease and therapeutic intervention. Annu Rev Med 66(1):311\u2013328. https:\/\/doi.org\/10.1146\/annurev-med-051113-024537","journal-title":"Annu Rev Med"},{"issue":"12","key":"11847_CR2","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/nrd.2017.201","volume":"16","author":"DM Schwartz","year":"2017","unstructured":"Schwartz DM, Kanno Y, Villarino AV, Ward M, Gadina M, O\u2019Shea JJ (2017) JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discovery 16(12):843\u2013862. https:\/\/doi.org\/10.1038\/nrd.2017.201","journal-title":"Nat Rev Drug Discovery"},{"key":"11847_CR3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.cbpa.2016.03.006","volume":"32","author":"K Yamaoka","year":"2016","unstructured":"Yamaoka K (2016) Janus kinase inhibitors for rheumatoid arthritis. Curr Opin Chem Biol 32:29\u201333. https:\/\/doi.org\/10.1016\/j.cbpa.2016.03.006","journal-title":"Curr Opin Chem Biol"},{"issue":"2","key":"11847_CR4","first-page":"318","volume":"34","author":"JA Hodge","year":"2016","unstructured":"Hodge JA, Kawabata TT, Krishnaswami S, Clark JD, Telliez JB, Dowty ME, Zwillich S (2016) The mechanism of action of tofacitinib\u2014An oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Clin Exp Rheumatol 34(2):318\u2013328","journal-title":"Clin Exp Rheumatol"},{"issue":"12","key":"11847_CR5","doi-asserted-by":"publisher","first-page":"5023","DOI":"10.1021\/jm401490p","volume":"57","author":"JD Clark","year":"2014","unstructured":"Clark JD, Flanagan ME, Telliez JB (2014) Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases. J Med Chem 57(12):5023\u20135038. https:\/\/doi.org\/10.1021\/jm401490p","journal-title":"J Med Chem"},{"issue":"10","key":"11847_CR6","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1080\/14656566.2016.1195812","volume":"17","author":"M Galluzzo","year":"2016","unstructured":"Galluzzo M, D\u2019Adamio S, Servoli S, Talamonti M (2016) Tofacitinib for the treatment of psoriasis. Expert Opin Pharmacother 17(10):1421\u20131433. https:\/\/doi.org\/10.1080\/14656566.2016.1195812","journal-title":"Expert Opin Pharmacother"},{"key":"11847_CR7","doi-asserted-by":"publisher","first-page":"397","DOI":"10.2147\/CCID.S53985","volume":"8","author":"AC Villasante Fricke","year":"2015","unstructured":"Villasante Fricke AC, Miteva M (2015) Epidemiology and burden of alopecia areata: A systematic review. Clin Cosmet Invest Dermatology 8:397\u2013403. https:\/\/doi.org\/10.2147\/CCID.S53985","journal-title":"Clin Cosmet Invest Dermatology"},{"issue":"1","key":"11847_CR8","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/s41392-023-01468-7","volume":"8","author":"C Xue","year":"2023","unstructured":"Xue C, Yao Q, Gu X, Shi Q, Yuan X, Chu Q, Li L (2023) Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer. Signal Transduct Target therapy 8(1):204","journal-title":"Signal Transduct Target therapy"},{"issue":"1","key":"11847_CR9","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4049\/jimmunol.1401867","volume":"204","author":"AV Villarino","year":"2020","unstructured":"Villarino AV, Kanno Y, O\u2019Shea JJ (2020) Mechanisms of JAK\/STAT signaling in immunity and disease. J Immunol 204(1):21\u201327","journal-title":"J Immunol"},{"issue":"11","key":"11847_CR10","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/nrc2734","volume":"9","author":"H Yu","year":"2009","unstructured":"Yu H, Pardoll D, Jove R (2009) STATs in cancer inflammation and immunity: A leading role for STAT3. Nat Rev Cancer 9(11):798\u2013809","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"11847_CR11","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/nri2093","volume":"7","author":"A Yoshimura","year":"2007","unstructured":"Yoshimura A, Naka T, Kubo M (2007) Suppressor of cytokine signaling (SOCS) proteins, cytokine signaling, and immune regulation. Nat Rev Immunol 7(6):454\u2013465","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"11847_CR12","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","volume":"6","author":"X Hu","year":"2021","unstructured":"Hu X, Li J, Fu M, Zhao X, Wang W (2021) The JAK\/STAT signaling pathway: From bench to clinic. Signal Transduct Target Therapy 6(1):402","journal-title":"Signal Transduct Target Therapy"},{"key":"11847_CR13","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1007\/s10875-021-00980-1","volume":"41","author":"SG Tangye","year":"2021","unstructured":"Tangye SG, Al-Herz W, Bousfiha A, Chatila T, Cunningham-Rundles C, Etzioni A, Sullivan KE (2021) The ever-increasing array of novel inborn errors of immunity: An interim update by the IUIS Committee. J Clin Immunol 41:666\u2013679. https:\/\/doi.org\/10.1007\/s10875-021-00980-1","journal-title":"J Clin Immunol"},{"issue":"24","key":"11847_CR14","doi-asserted-by":"publisher","first-page":"13976","DOI":"10.1074\/jbc.271.24.13976","volume":"271","author":"JW Verbsky","year":"1996","unstructured":"Verbsky JW, Bach EA, Fang YF, Yang L, Kingston AK, Schreiber RD (1996) Expression of Janus kinase 3 in human endothelial and other non-lymphoid and non-myeloid cells. J Biol Chem 271(24):13976\u201313980. https:\/\/doi.org\/10.1074\/jbc.271.24.13976","journal-title":"J Biol Chem"},{"issue":"2","key":"11847_CR15","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/0092-8674(93)90414-L","volume":"74","author":"BA Witthuhn","year":"1993","unstructured":"Witthuhn BA, Quelle FW, Silvennoinen O, Yi T, Tang B, Miura O, Ihle JN (1993) JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell 74(2):227\u2013236","journal-title":"Cell"},{"key":"11847_CR16","unstructured":"Leonard WJ (1999) Type I cytokines and interferons and their receptors. In: Paul WE (ed) Fundamental Immunology, 4th edn. Lippincott Raven, pp 741\u2013774"},{"issue":"5332","key":"11847_CR17","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1126\/science.277.5332.1630","volume":"277","author":"JE Darnell Jr","year":"1997","unstructured":"Darnell JE Jr. (1997) STATs and gene regulation. Science 277(5332):1630\u20131635","journal-title":"Science"},{"key":"11847_CR18","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1146\/annurev.immunol.16.1.293","volume":"16","author":"WJ Leonard","year":"1998","unstructured":"Leonard WJ, O\u2019Shea JJ (1998) Jaks and STATs: Biological implications. Annu Rev Immunol 16:293\u2013322","journal-title":"Annu Rev Immunol"},{"issue":"3","key":"11847_CR19","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3109\/00365548.2012.715750","volume":"45","author":"TH Mogensen","year":"2013","unstructured":"Mogensen TH, Jakobsen MA, Jensen SB, Larsen CS, Paludan SR (2013) Identification of a novel STAT3 mutation in a patient with hyper-IgE syndrome. Scand J Infect Dis 45(3):235\u2013238","journal-title":"Scand J Infect Dis"},{"issue":"2","key":"11847_CR20","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.bbadis.2010.05.012","volume":"1812","author":"AE Lovett-Racke","year":"2011","unstructured":"Lovett-Racke AE, Yang Y, Racke MK (2011) Th1 versus Th17: Are T cell cytokines relevant in multiple sclerosis? Biochimica et Biophysica Acta (BBA)\u2014Molecular. Basis Disease 1812(2):246\u2013251","journal-title":"Basis Disease"},{"issue":"5","key":"11847_CR21","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1172\/JCI200112563","volume":"108","author":"T Chitnis","year":"2001","unstructured":"Chitnis T, Najafian N, Abdallah KA, Dong V, Yagita H, Sayegh MH, Khoury SJ (2001) Effect of targeted disruption of STAT4 and STAT6 on the induction of experimental autoimmune encephalomyelitis. J Clin Invest 108(5):739\u2013747","journal-title":"J Clin Invest"},{"issue":"8","key":"11847_CR22","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/nrd4088","volume":"12","author":"G Miklossy","year":"2013","unstructured":"Miklossy G, Hilliard TS, Turkson J (2013) Therapeutic modulators of STAT signalling for human diseases. Nat Rev Drug Discovery 12(8):611\u2013629","journal-title":"Nat Rev Drug Discovery"},{"issue":"4","key":"11847_CR23","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/ki.2010.438","volume":"79","author":"J Menke","year":"2011","unstructured":"Menke J, Hsu PH, Dionne MA, Victor GC, Baron GS, Wright J, Kelley VR (2011) Targeting transcription factor Stat4 uncovers a role for interleukin-18 in the pathogenesis of severe lupus nephritis in mice. Kidney Int 79(4):452\u2013463","journal-title":"Kidney Int"},{"issue":"21","key":"11847_CR24","doi-asserted-by":"publisher","first-page":"2566","DOI":"10.1038\/sj.onc.1203523","volume":"19","author":"JX Lin","year":"2000","unstructured":"Lin JX, Leonard WJ (2000) The role of Stat5a and Stat5b in signaling by IL-2 family cytokines. Oncogene 19(21):2566\u20132576","journal-title":"Oncogene"},{"issue":"1","key":"11847_CR25","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1182\/blood-2002-03-0740","volume":"101","author":"M Buitenhuis","year":"2003","unstructured":"Buitenhuis M, Baltus B, Lammers JW, Coffer PJ, Koenderman L (2003) Signal transducer and activator of transcription 5a (STAT5a) is required for eosinophil differentiation of human cord blood-derived CD34\u2009+\u2009cells. Blood 101(1):134\u2013142","journal-title":"Blood"},{"key":"11847_CR26","doi-asserted-by":"crossref","unstructured":"Udy GB, Towers RP, Snell RG, Wilkins RJ, Park SH, Rampaul AS, Davey HW (1997) Requirement of STAT5b for sexual dimorphism of body growth rates and liver gene expression. Proceedings Nat Academy Sci 94(14):7239\u20137244","DOI":"10.1073\/pnas.94.14.7239"},{"issue":"11","key":"11847_CR27","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1084\/jem.188.11.2067","volume":"188","author":"K Imada","year":"1998","unstructured":"Imada K, Bloom ET, Nakajima H, Horvath-Arcidiacono JA, Udy GB, Davey HW, Leonard WJ (1998) Stat5b is essential for natural killer cell-mediated proliferation and cytolytic activity. J Exp Med 188(11):2067\u20132074","journal-title":"J Exp Med"},{"issue":"12","key":"11847_CR28","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1021\/cb7001973","volume":"2","author":"K Siddiquee","year":"2007","unstructured":"Siddiquee K, Zhang S, Guida WC, Blaskovich MA, Greedy B, Lawrence HR, Turkson J (2007) An oxazole-based small molecule Stat3 inhibitor modulates Stat3 stability and processing and induces antitumor cell effects. ACS Chem Biol 2(12):787\u2013798","journal-title":"ACS Chem Biol"},{"issue":"4","key":"11847_CR29","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/ni.3691","volume":"18","author":"AV Villarino","year":"2017","unstructured":"Villarino AV, Kanno Y, Ferdinand JR, O\u2019Shea JJ (2017) Mechanisms and consequences of Jak-STAT signaling in the immune system. Nat Immunol 18(4):374\u2013384","journal-title":"Nat Immunol"},{"issue":"1","key":"11847_CR30","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/s41392-023-01468-7","volume":"8","author":"C Xue","year":"2023","unstructured":"Xue C, Yao Q, Gu X, Shi Q, Yuan X, Chu Q (2023) Evolving cognition of the JAK-STAT signaling pathway: Autoimmune disorders and cancer. Signal Transduct Target Therapy 8(1):204. https:\/\/doi.org\/10.1038\/s41392-023-01468-7","journal-title":"Signal Transduct Target Therapy"},{"issue":"11","key":"11847_CR31","first-page":"867","volume":"181","author":"F Seif","year":"2020","unstructured":"Seif F, Aazami H, Khoshmirsafa M, Shemirani S, Sajadian A, Mansouri R (2020) JAK inhibition as a new treatment strategy for patients with COVID-19. Int Arch Allergy Immunol 181(11):867\u2013875","journal-title":"Int Arch Allergy Immunol"},{"key":"11847_CR32","doi-asserted-by":"crossref","unstructured":"Owen KL, Brockwell NK, Parker BS (2019) JAK-STAT signaling: A double-edged sword of immune regulation and cancer progression. Cancers 11(12):2002","DOI":"10.3390\/cancers11122002"},{"issue":"3","key":"11847_CR33","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/bjc2015.233","volume":"113","author":"SJ Thomas","year":"2015","unstructured":"Thomas SJ, Snowden JA, Zeidler MP, Danson SJ (2015) The role of JAK\/STAT signalling in the pathogenesis, prognosis, and treatment of solid tumours. Br J Cancer 113(3):365\u2013371. https:\/\/doi.org\/10.1038\/bjc2015.233","journal-title":"Br J Cancer"},{"key":"11847_CR34","doi-asserted-by":"publisher","unstructured":"Baratchian M, Tiwary S, Sivakamasundari V, Huang RL, Cheng AS (2022) H3K9 methylation drives resistance to androgen receptor-antagonist therapy in prostate cancer. Proceedings of the National Academy of Sciences 119(3):e2114324119. https:\/\/doi.org\/10.1073\/pnas.2114324119","DOI":"10.1073\/pnas.2114324119"},{"issue":"3","key":"11847_CR35","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1080\/10428190801895360","volume":"49","author":"A Tefferi","year":"2008","unstructured":"Tefferi A (2008) JAK and MPL mutations in myeloid malignancies. Leuk Lymphoma 49(3):388\u2013397","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"11847_CR36","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1002\/ajh.22063","volume":"86","author":"LM Scott","year":"2011","unstructured":"Scott LM (2011) The JAK2 exon 12 mutations: A comprehensive review. Am J Hematol 86(8):668\u2013676","journal-title":"Am J Hematol"},{"issue":"8","key":"11847_CR37","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1038\/ng.2698","volume":"45","author":"H Sakaguchi","year":"2013","unstructured":"Sakaguchi H, Okuno Y, Muramatsu H, Makishima H, Shiraishi Y, Mizoguchi M, Kojima S (2013) Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia. Nat Genet 45(8):937\u2013941","journal-title":"Nat Genet"},{"issue":"5","key":"11847_CR38","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.immuni.2014.03.010","volume":"40","author":"I Kryczek","year":"2014","unstructured":"Kryczek I, Lin Y, Nagarsheth N, Peng D, Zhao L, Zhao E, Zou W (2014) IL-22\u2009+\u2009CD4+ T cells promote colorectal cancer stemness via STAT3 transcription factor activation and induction of the methyltransferase DOT1L. Immunity 40(5):772\u2013784","journal-title":"Immunity"},{"issue":"7","key":"11847_CR39","doi-asserted-by":"publisher","first-page":"3701","DOI":"10.1182\/blood-2007-09-111948","volume":"111","author":"LT Lam","year":"2008","unstructured":"Lam LT, Wright G, Davis RE, Lenz G, Farinha P, Dang L, L. M. S (2008) Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-\u03baB pathways in subtypes of diffuse large B-cell lymphoma. Blood 111(7):3701\u20133713","journal-title":"Blood"},{"issue":"11","key":"11847_CR40","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/nrc2734","volume":"9","author":"H Yu","year":"2009","unstructured":"Yu H, Pardoll D, Jove R (2009) STATs in cancer inflammation and immunity: A leading role for STAT3. Nat Rev Cancer 9(11):798\u2013809","journal-title":"Nat Rev Cancer"},{"issue":"22","key":"11847_CR41","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.1182\/blood-2012-12-474577","volume":"121","author":"HL Rajala","year":"2013","unstructured":"Rajala HL, Eldfors S, Kuusanmaki H, van Adrichem AJ, Olson T, Lagstr\u00f6m S, Mustjoki S (2013) Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia. Blood 121(22):4541\u20134550","journal-title":"Blood"},{"issue":"2","key":"11847_CR42","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.iac.2008.01.005","volume":"28","author":"AF Freeman","year":"2008","unstructured":"Freeman AF, Holland SM (2008) The hyper-IgE syndromes. Immunol Allergy Clin North Am 28(2):277\u2013291. https:\/\/doi.org\/10.1016\/j.iac.2008.01.005","journal-title":"Immunol Allergy Clin North Am"},{"key":"11847_CR43","doi-asserted-by":"publisher","unstructured":"Milner JD, Vogel TP, Forbes L, Ma CA, Stray-Pedersen A, Niemela JJ, \u2026 Gulen F (2015). Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations. Blood 125(4):591\u2013599. https:\/\/doi.org\/10.1182\/blood-2014-09-602763","DOI":"10.1182\/blood-2014-09-602763"},{"issue":"8","key":"11847_CR44","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1038\/ng.3040","volume":"46","author":"SE Flanagan","year":"2014","unstructured":"Flanagan SE, Haapaniemi E, Russell MA, Caswell R, Lango Allen H, De Franco E, Ellard S (2014) Activating germline mutations in STAT3 cause early-onset multi-organ autoimmune disease. Nat Genet 46(8):812\u2013814. https:\/\/doi.org\/10.1038\/ng.3040","journal-title":"Nat Genet"},{"issue":"1","key":"11847_CR45","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.it.2019.11.008","volume":"41","author":"DF Tough","year":"2020","unstructured":"Tough DF, Rioja I, Modis LK, Prinjha RK (2020) Epigenetic regulation of T cell memory: Recalling therapeutic implications. Trends Immunol 41(1):29\u201345. https:\/\/doi.org\/10.1016\/j.it.2019.11.008","journal-title":"Trends Immunol"},{"issue":"1","key":"11847_CR46","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/978-3-319-66884-0_19","volume":"19","author":"A Kim","year":"2018","unstructured":"Kim A, Strober B (2018) Janus kinase inhibitors. Biol Systemic Agents Dermatology 19(1):187\u2013198. https:\/\/doi.org\/10.1007\/978-3-319-66884-0_19","journal-title":"Biol Systemic Agents Dermatology"},{"issue":"1","key":"11847_CR47","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12943-020-01258-7","volume":"19","author":"S Zou","year":"2020","unstructured":"Zou S, Tong Q, Liu B, Huang W, Tian Y, Fu Z (2020) Targeting STAT3 in cancer immunotherapy. Mol Cancer 19(1):145. https:\/\/doi.org\/10.1186\/s12943-020-01258-7","journal-title":"Mol Cancer"},{"issue":"2","key":"11847_CR48","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/pros.22741","volume":"74","author":"C Liu","year":"2014","unstructured":"Liu C, Lou W, Zhu Y, Nadiminty N, Schwartz CT, Evans CP, Gao AC (2014) Inhibition of constitutively active Stat3 reverses enzalutamide resistance in LNCaP derivative prostate cancer cells. Prostate 74(2):201\u2013209. https:\/\/doi.org\/10.1002\/pros.22741","journal-title":"Prostate"},{"issue":"4","key":"11847_CR49","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","volume":"15","author":"DE Johnson","year":"2018","unstructured":"Johnson DE, O\u2019Keefe RA, Grandis JR (2018) Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer. Nat Reviews Clin Oncol 15(4):234\u2013248. https:\/\/doi.org\/10.1038\/nrclinonc.2018.8","journal-title":"Nat Reviews Clin Oncol"},{"key":"11847_CR50","doi-asserted-by":"publisher","unstructured":"Wang T, Fahrmann JF, Lee H, Li YJ, Roach GD, Bhardwaj V, \u2026 Jove R (2018). JAK\/STAT3-regulated fatty acid \u03b2-oxidation is critical for breast cancer stem cell self-renewal and chemoresistance. Cell Metabolism 27(1):136\u2013150. https:\/\/doi.org\/10.1016\/j.cmet.2017.11.001","DOI":"10.1016\/j.cmet.2017.11.001"},{"key":"11847_CR51","doi-asserted-by":"publisher","first-page":"100903","DOI":"10.1016\/j.drup.2022.100903","volume":"66","author":"C Liu","year":"2023","unstructured":"Liu C, Wang J, Liu X, Wang J, Lou W, Nadiminty N, Gao AC (2023) A highly potent small-molecule antagonist of exportin-1 selectively eliminates CD44\u2009+\u2009CD24\u2013enriched breast cancer stem-like cells. Drug Resist Updates 66:100903. https:\/\/doi.org\/10.1016\/j.drup.2022.100903","journal-title":"Drug Resist Updates"},{"issue":"1","key":"11847_CR52","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s12943-022-01679-6","volume":"21","author":"D Meraviglia-Crivelli","year":"2022","unstructured":"Meraviglia-Crivelli D, Zheleva A, Villanueva H, Mansilla C, Moreno-Cugat A (2022) IL-6\/STAT3 signaling in tumor cells restricts the expression of frameshift-derived neoantigens by SMG1 induction. Mol Cancer 21(1):211. https:\/\/doi.org\/10.1186\/s12943-022-01679-6","journal-title":"Mol Cancer"},{"issue":"3","key":"11847_CR53","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s10549-013-2488-z","volume":"138","author":"C Dethlefsen","year":"2013","unstructured":"Dethlefsen C, H\u00f8jfeldt G, Hojman P (2013) The role of intratumoral and systemic IL-6 in breast cancer. Breast Cancer Res Treat 138(3):657\u2013664. https:\/\/doi.org\/10.1007\/s10549-013-2488-z","journal-title":"Breast Cancer Res Treat"},{"key":"11847_CR54","doi-asserted-by":"publisher","unstructured":"Rodr\u00edguez-Barrueco R, Yu J, Saucedo-Cuevas LP, Olivan M, Llobet-Navas D, Putcha P, \u2026 Silva JM (2015). Inhibition of the autocrine IL-6-JAK2-STAT3-calprotectin axis as targeted therapy for HR-\/HER2\u2009+\u2009breast cancers. Genes & Development 29(15):1631\u20131648. https:\/\/doi.org\/10.1101\/gad.262642.115","DOI":"10.1101\/gad.262642.115"},{"issue":"3","key":"11847_CR55","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1111\/j.1365-2141.2011.08632.x","volume":"153","author":"K Butterbach","year":"2011","unstructured":"Butterbach K, Beckmann L, de Sanjose S, Benavente Y, Nieters A, Becker N (2011) Association of JAK-STAT pathway-related genes with lymphoma risk: Results of a European case-control study (EpiLymph). Br J Haematol 153(3):318\u2013333","journal-title":"Br J Haematol"},{"key":"11847_CR56","doi-asserted-by":"crossref","unstructured":"Ellinghaus D, Ellinghaus E, Nair RP, Stuart PE, Rodriguez E, Arning A, \u2026 Franke A (2012). Combined analysis of genome-wide association studies for Crohn disease and psoriasis identifies seven shared susceptibility loci. American J Human Genetics 90(4):636\u2013647","DOI":"10.1016\/j.ajhg.2012.02.020"},{"issue":"15","key":"11847_CR57","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1182\/blood-2012-06-435297","volume":"120","author":"A Jerez","year":"2012","unstructured":"Jerez A, Clemente MJ, Makishima H, Koskela H, Leblanc F, Peng Ng KP, Maciejewski JP (2012) STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood 120(15):3048\u20133057","journal-title":"Blood"},{"issue":"6","key":"11847_CR58","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1093\/hmg\/11.6.613","volume":"11","author":"G Duetsch","year":"2002","unstructured":"Duetsch G, Illig T, Loesgen S, Mutius EV, Gohlke H, Roell G, Wjst M (2002) STAT6 as an asthma candidate gene: Polymorphism screening, association and haplotype analysis in a Caucasian sib-pair study. Hum Mol Genet 11(6):613\u2013621","journal-title":"Hum Mol Genet"},{"key":"11847_CR59","doi-asserted-by":"crossref","unstructured":"Braig M, Lee S, Loddenkemper C, Rudolph C, Peters AH, Schlegelberger B, \u2026 Schmitt CA (2005). Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 436(7051):660\u2013665","DOI":"10.1038\/nature03841"},{"issue":"5570","key":"11847_CR60","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1126\/science.1069861","volume":"296","author":"H Ogawa","year":"2002","unstructured":"Ogawa H, Ishiguro KI, Gaubatz S, Livingston DM, Nakatani Y (2002) A complex with chromatin modifiers that occupies E2F- and Myc-responsive genes in G0 cells. Science 296(5570):1132\u20131136","journal-title":"Science"},{"issue":"4","key":"11847_CR61","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/ncb1713","volume":"10","author":"S Shi","year":"2008","unstructured":"Shi S, Larson K, Guo D, Lim SJ, Dutta P, Yan SJ, Li WX (2008) Drosophila STAT is required for directly maintaining HP1 localization and heterochromatin stability. Nat Cell Biol 10(4):489\u2013496","journal-title":"Nat Cell Biol"},{"key":"11847_CR62","doi-asserted-by":"crossref","unstructured":"Linossi EM, Li K, Veggiani G, Tan C, Dehkhoda F, Hockings C, \u2026 Nicholson SE (2021). Discovery of an exosite on the SOCS2-SH2 domain that enhances SH2 binding to phosphorylated ligands. Nature Comm 12(1):7032","DOI":"10.1038\/s41467-021-26983-5"},{"issue":"2","key":"11847_CR63","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.immuni.2012.01.010","volume":"36","author":"A Yoshimura","year":"2012","unstructured":"Yoshimura A, Yasukawa H (2012) JAK\u2019s SOCS: A mechanism of inhibition. Immunity 36(2):157\u2013159","journal-title":"Immunity"},{"issue":"11","key":"11847_CR64","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1002\/jcph.734","volume":"56","author":"M Lamba","year":"2016","unstructured":"Lamba M, Wang R, Fletcher T, Alvey C, Kushner J, IV, Stock TC (2016) Extended-release once-daily formulation of tofacitinib: Evaluation of pharmacokinetics compared with immediate-release tofacitinib and impact of food. J Clin Pharmacol 56(11):1362\u20131371","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"11847_CR65","first-page":"33","volume":"12","author":"JJ O\u2019Shea","year":"2012","unstructured":"O\u2019Shea JJ, Plenge R (2012) JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Nat Rev Immunol 12(1):33\u201344","journal-title":"Nat Rev Immunol"},{"key":"11847_CR66","unstructured":"Kremer JM, Li ZG, Hall S, Fleischmann R, Genovese M, Martin-Mola E, \u2026 Bradley JD (2016). Tofacitinib or adalimumab in rheumatoid arthritis. New England J Med 374(26):2534\u20132548"},{"key":"11847_CR67","doi-asserted-by":"crossref","unstructured":"Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, \u2026 Tefferi A (2010). Ruxolitinib for myelofibrosis. New England J Med 363(12):1117\u20131127","DOI":"10.1056\/NEJMoa1002028"},{"key":"11847_CR68","unstructured":"Takeuchi T, Genovese MC, Haraoui B, Li Z, Xie L, Chu BC, \u2026 Smolen JS (2016). Baricitinib in rheumatoid arthritis. The Lancet 387(10037):79\u201388"},{"key":"11847_CR69","unstructured":"Sandborn WJ, Su C, Sands BE, D\u2019Haens GR, Vermeire S, Schreiber S, \u2026 Panes J (2017). Tofacitinib in patients with moderate or severe ulcerative colitis. New England J Med 376(17):1626\u20131636"},{"key":"11847_CR70","unstructured":"Younes A, Burke JM, Cheson BD, Diefenbach C, Ferrari S, Kahn SE, \u2026 de Vos S (2019). AZD9150, an antisense oligonucleotide targeting STAT3, in patients with relapsed or refractory lymphoma. Lancet Oncology 20(6):682\u2013692"},{"issue":"24","key":"11847_CR71","first-page":"14220","volume":"63","author":"L Miao","year":"2020","unstructured":"Miao L, Yang Q, Tan MS, Zhang R (2020) Peptide-based inhibitors of STAT3 and SH2 domain interactions. J Med Chem 63(24):14220\u201314232","journal-title":"J Med Chem"},{"issue":"1","key":"11847_CR72","first-page":"44","volume":"58","author":"C Yang","year":"2020","unstructured":"Yang C, Chen J, Wang L (2020) IL-6 inhibitors in autoimmune diseases: Mechanisms and clinical applications. Clin Rev Allergy Immunol 58(1):44\u201354","journal-title":"Clin Rev Allergy Immunol"},{"issue":"7","key":"11847_CR73","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s11926-017-0665-5","volume":"19","author":"M Cutolo","year":"2017","unstructured":"Cutolo M, Campitiello R, Gotelli E, Soldano S (2017) Anti-TNF therapy in autoimmune diseases: Mechanisms and clinical outcomes. Curr Rheumatol Rep 19(7):42","journal-title":"Curr Rheumatol Rep"},{"issue":"1","key":"11847_CR74","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrrheum.2015.167","volume":"12","author":"DM Schwartz","year":"2016","unstructured":"Schwartz DM, Bonelli M, Gadina M, O\u2019Shea JJ (2016) Type I\/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol 12(1):25\u201336","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"11847_CR75","first-page":"143","volume":"14","author":"AL Basquiera","year":"2009","unstructured":"Basquiera AL, Soria NW, Ryser R, Garcia J (2009) Clinical significance of the V617F mutation of the JAK2 gene in patients with chronic myeloproliferative disorders. Hematology 14(3):143\u2013147","journal-title":"Hematology"},{"key":"11847_CR76","first-page":"63","volume":"365","author":"RL Levine","year":"2012","unstructured":"Levine RL (2012) JAK-mutant myeloproliferative neoplasms. Curr Top Microbiol Immunol 365:63\u201380","journal-title":"Curr Top Microbiol Immunol"},{"key":"11847_CR77","doi-asserted-by":"crossref","unstructured":"Jeong EG, Kim MS, Nam HK, Min CK, Lee S, Chung YJ, \u2026 Lee SH (2008). Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers. Clinical Cancer Research 14(12):3716\u20133721","DOI":"10.1158\/1078-0432.CCR-07-4839"},{"issue":"14","key":"11847_CR78","doi-asserted-by":"publisher","first-page":"3911","DOI":"10.1182\/blood-2010-12-319467","volume":"118","author":"NE Elliott","year":"2011","unstructured":"Elliott NE, Cleveland SM, Grann V, Janik J, Waldmann TA, Dav\u00e9 UP (2011) FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia\/lymphoma. Blood 118(14):3911\u20133921","journal-title":"Blood"},{"issue":"3","key":"11847_CR79","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/S0092-8674(00)81166-6","volume":"93","author":"SJ Rodig","year":"1998","unstructured":"Rodig SJ, Meraz MA, White JM, Richter PA, Schreiber RD, Ihle JN (1998) Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell 93(3):373\u2013383","journal-title":"Cell"},{"issue":"5","key":"11847_CR80","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.4049\/jimmunol.1202859","volume":"191","author":"SJ Sohn","year":"2013","unstructured":"Sohn SJ, Barrett K, Van Abbema A, Cheng J, Williams SA (2013) A restricted role for TYK2 catalytic activity in human cytokine responses revealed by novel TYK2-selective inhibitors. J Immunol 191(5):2205\u20132216","journal-title":"J Immunol"},{"issue":"6544","key":"11847_CR81","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/377065a0","volume":"377","author":"P Macchi","year":"1995","unstructured":"Macchi P, Villa A, Giliani S, Sacco MG, Frattini A, Porta F, Notarangelo LD (1995) Mutations of the Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature 377(6544):65\u201368","journal-title":"Nature"},{"key":"11847_CR82","doi-asserted-by":"crossref","unstructured":"Russell SM, Tayebi N, Nakajima H, Riedy MC, Roberts JL, Aman MJ, \u2026 Leonard WJ (1995). Mutation of Jak3 in a patient with SCID: Essential role of Jak3 in lymphoid development. Science 270(5237):797\u2013800","DOI":"10.1126\/science.270.5237.797"},{"key":"11847_CR83","unstructured":"Furumoto Y, Smith CK, Blanco L, Zhao W, Brooks SR, Thacker SG, \u2026 Kaplan MJ (2016). Tofacitinib ameliorates murine lupus and its associated vascular dysfunction. Arthritis & Rheumatology 68(9):2163\u20132174"},{"issue":"8","key":"11847_CR84","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/exd.13060","volume":"25","author":"A Jabbari","year":"2016","unstructured":"Jabbari A, Nguyen N, Cerise JE, Chen G, Agalliu D, Clynes R (2016) Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers. Exp Dermatol 25(8):642\u2013643","journal-title":"Exp Dermatol"},{"key":"11847_CR85","doi-asserted-by":"crossref","unstructured":"Harel S, Higgins CA, Cerise JE, Dai Z, Chen JC, Clynes R, Christiano AM (2015) Pharmacologic inhibition of JAK\u2013STAT signaling promotes hair growth. Sci Adv 1(9):e1500973","DOI":"10.1126\/sciadv.1500973"},{"issue":"2","key":"11847_CR86","first-page":"123","volume":"11","author":"Q Jiang","year":"2022","unstructured":"Jiang Q, Wang Y, Li W (2022) Adverse events and resistance mechanisms of JAK inhibitors in clinical use. J Clin Med 11(2):123\u2013132","journal-title":"J Clin Med"},{"issue":"5","key":"11847_CR87","first-page":"1627","volume":"43","author":"RL Brenner","year":"2020","unstructured":"Brenner RL, Cheng H, Johnson A (2020) Secondary mutations in tyrosine kinases following JAK inhibitor therapy. Oncol Rep 43(5):1627\u20131634","journal-title":"Oncol Rep"},{"key":"11847_CR88","first-page":"720852","volume":"11","author":"X Li","year":"2021","unstructured":"Li X, Wu Y, Chen J (2021) Mechanisms of resistance to JAK2 inhibitors in myelofibrosis. Front Oncol 11:720852","journal-title":"Front Oncol"},{"key":"11847_CR89","first-page":"56","volume":"77","author":"JE Smith","year":"2019","unstructured":"Smith JE, Taylor L, Miller R (2019) Combination therapy of panobinostat and ruxolitinib in JAK2V617F positive models of myeloproliferative neoplasms. Leuk Res 77:56\u201365","journal-title":"Leuk Res"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-11847-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-11847-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-11847-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T13:04:12Z","timestamp":1778331852000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-11847-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,9]]},"references-count":89,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["11847"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-11847-2","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,9]]},"assertion":[{"value":"1 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Deceleration"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This review has no ethical approval; thus, this is a collection of the author\u2019s studies.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval and Consent to Participate"}},{"value":"This review has no ethical approval; thus, this is a collection of the author\u2019s studies.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"During the preparation of this manuscript, the authors used AI-assisted tools (ChatGPT, Gemini, and Canva) for figure preparation, graphical abstract design, and improvement of language clarity. The authors reviewed and edited all content and take full responsibility for the accuracy, integrity, and originality of the manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Generative AI and AI-assisted technologies"}}],"article-number":"732"}}